Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks |
| |
Authors: | Michael Fromm Wolfgang E Berdel Hans D Schick Susanne Danhauser-Riedl Ulrich Fink Wolfgang Remy Anneliese Reichert Anke Ankele Heinz W Präuer Jörg R Siewert Johann Rastetter |
| |
Institution: | (1) Division of Hematology and Oncology, Department of Medicine I, Technische Universität, Ismaninger Str. 22, 80 Munich, FRG;(2) Department of Dermatology, Technische Universität, Ismaninger Str. 22, 80 Munich, FRG;(3) Department of Surgery, Technische Universität, Ismaninger Str. 22, 80 Munich, FRG;(4) Division of Hematology and Oncology, Department of Medicine I, Technische Universität, Ismaninger Str. 22, 80 Munich, FRG |
| |
Abstract: | Summary Carbetimer, a new synthetic low molecular weight polyelectrolyte with a novel structure displayed antitumor activiy in a number of animal tumor model systems and in vitro investigations. Based on these findings it was brought to a phase I clinical trial in patients with advanced malignant disease after failure of conventional treatment or with no conventional treatment available. Forty-eight patients received 98 courses. The schedule was a one hour i.v. infusion every four weeks. The starting dose was 180 mg/m2 and dose escalation was performed according to a modified Fibonacci formula up to 16,690 mg/m2. At least three patients were treated at each dose level and each patient was eligible to receive repeat courses at the same dose, until progressive disease or dose-limiting toxicity intervened. No hematological toxicity was encountered. Some adverse effects such as reversible proteinuria, hypercalcaemia, pain at infusion site, nausea and vomiting and fatigue were seen partly in a dose-related manner but did not represent the maximum tolerated dose (MTD). The limiting toxicity at the highest dose level of 16,690 mg/m2 consisted of ocular symptoms (light flashes) accompanied by a modest decrease of blood pressure and nausea or vomiting during a one hour infusion. 16,690 mg/m2/1 hour was considered the MTD. There were four deaths on study, all considered diseaserelated. Fourteen patients had stable disease for more than two courses, which, however, could also be explained by the natural course of disease. No clear-cut antitumor responses were noted in our study center.The recommended dose for phase II trials derived from our results is 12,550 mg/m2/2 hours. However, with regard to experiences in other phase I studies, the subsequent phase II studies will be performed with a dose of 6,500 mg/m2. |
| |
Keywords: | carbetimer phase I trial cancer patients |
本文献已被 SpringerLink 等数据库收录! |
|